Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials. Issue 10 (October 2013)

• Record Type: Journal Article
• Authors: Solh, Melhem; Fisher, Richard I.; Goy, André; de Vos, Sven; Bernstein, Steven H.; Esseltine, Dixie-Lee; Neuwirth, Rachel; Morrison, Vicki A.
• Is Part Of: Leukemia & lymphoma. Volume 54:Issue 10(2013:Oct.)
• Page Start: 2185
• Page End: 2189
• Publication Date: 2013-10
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2013.772294
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>The incidence of herpes zoster (HZ) in patients with non-Hodgkin lymphoma (NHL) receiving bortezomib-based therapy has not been well studied. We reviewed data from two phase II trials in which bortezomib was administered to 236 patients, median age 65 years, with relapsed/refractory mantle cell or indolent NHL. HZ occurred in 24 patients (10.2%) overall, with a comparable incidence in NHL histologic subgroups. Median time to HZ was 39 (range, 11–206) days. In total, 71% of patients who developed HZ were aged ≥ 65 years, compared to 48% without HZ (<italic>p</italic> = 0.03). Patients with HZ were more likely to have had received ≥ 2 lines of therapy (63% vs. 47%, <italic>p</italic> = 0.16). Six (25%) of the patients who developed HZ had received purine analogs, compared with 34 (16%) patients without HZ (<italic>p</italic> = 0.27). As the occurrence of HZ may complicate the course of indolent or mantle cell NHL in patients receiving bortezomib-based therapies, these patients, especially the elderly, should be strongly considered for antiviral prophylaxis.</p> </abstract>